Adma Biologics Inc Revenue Growth Rates (ADMA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Adma Biologics Inc   (NASDAQ: ADMA)
 

ADMA's Revenue Growth by Quarter and Year

Adma Biologics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADMA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 124.40
1st Quarter March 113.75
FY 238.14

ADMAs Annual Revenue
Adma Biologics Inc 's Revenue in the fiscal year 2025 $ 510.17 millions
Adma Biologics Inc 's Revenue in the fiscal year 2024 $ 425.55 millions
Adma Biologics Inc 's Revenue in the fiscal year 2023 $ 257.94 millions
Adma Biologics Inc 's Revenue in the fiscal year 2022 $ 154.08 millions
Adma Biologics Inc 's Revenue in the fiscal year 2021 $ 80.94 millions




ADMA Revenue second quarter 2026 Y/Y Growth Comment
Adma Biologics Inc reported Revenue growth of 2.61% year on year in the second quarter 2026, to $ 124.40 millions, this is lower than Adma Biologics Inc 's recent average Revenue rise of 57.67%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 38 other companies have achieved higher Revenue growth. While Adma Biologics Inc ' s Revenue increase of 2.61% ranks overall at the positon no. 2271 in the second quarter 2026.


ADMA Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 18.38 % 59.07 % 47.86 %
3rd Quarter September - 11.67 % 79.53 % 62.2 %
2nd Quarter June 2.61 % 13.88 % 78.34 % 76.02 %
1st Quarter March -0.31 % 40.67 % 42.52 % 95.57 %
FY   - 19.62 % 65.18 % -

Financial Statements
Adma Biologics Inc 's second quarter 2026 Revenue $ 124.40 millions ADMA's Income Statement
Adma Biologics Inc 's second quarter 2025 Revenue $ 121.23 millions Quarterly ADMA's Income Statement


ADMA Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 4.14 % -1.76 % 10.88 %
3rd Quarter September - 10.23 % 12.41 % 11.66 %
2nd Quarter June 9.36 % 6.25 % 31.24 % 4.88 %
1st Quarter March -18.26 % -2.93 % 9.76 % 13.87 %
FY (Year on Year)   - 19.62 % 65.18 % -


Back to ADMA Growth rate Comparisons >> Back to ADMA Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #39
Healthcare Sector #331
Overall #2271

Revenue Y/Y Growth Statistics
High Average Low
187.12 % 57.67 % -31.86 %
(Dec 31 2013)   (Mar 31 2019)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #39
Healthcare Sector #331
Overall #2271
Revenue Y/Y Growth Statistics
High Average Low
187.12 % 57.67 % -31.86 %
(Dec 31 2013)   (Mar 31 2019)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Adma Biologics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
5129.45 % 108.74 % -66.32 %
(Jun 30 2012)  


ADMA's II. Quarter Q/Q Revenue Comment
Adma Biologics Inc achieved in the II. Quarter 2026 below company average Revenue increase of 9.36% quarter on quarter, to $ 124.40 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 6.25% growth in the II. Quarter a year ago

Within Biotechnology & Pharmaceuticals industry 17 other companies have achieved higher Revenue quarter on quarter growth. While Adma Biologics Inc 's Revenue growth quarter on quarter, overall rank is 845.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #18
Healthcare Sector #127
Overall #845
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #18
Healthcare Sector #127
Overall #845
Revenue Q/Q Growth Statistics
High Average Low
5129.45 % 108.74 % -66.32 %
(Jun 30 2012)  


ADMA's II. Quarter Q/Q Revenue Comment
Adma Biologics Inc achieved in the II. Quarter 2026 below company average Revenue increase of 9.36% quarter on quarter, to $ 124.40 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 6.25% in the II. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 17 other companies have achieved higher Revenue quarter on quarter growth. While Adma Biologics Inc 's Revenue growth quarter on quarter, overall rank is 845.


Adma Biologics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 510.93 $ 507.77 $ 508.11 $ 486.50 $ 472.53
Y / Y Revenue Growth (TTM) 8.13 % 10.92 % 19.62 % 27.65 % 44.01 %
Year on Year Revenue Growth Overall Ranking # 385 # 148 # 137 # 175 # 59
Seqeuential Revenue Change (TTM) 0.62 % -0.07 % 4.44 % 2.96 % 3.23 %
Seq. Revenue Growth (TTM) Overall Ranking # 2271 # 564 # 614 # 703 # 529


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Adma Biologics Inc 's cumulative twelve months Revenue were $ 511 millions, company would post below average annual Revenue growth of 3.23% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Adma Biologics Inc 's Revenue growth from the 113.75% growth in Mar 31 2026.

In the Healthcare sector 98 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 148 to 385.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 39
Healthcare Sector # 99
Overall # 385

Revenue TTM Y/Y Growth Statistics
High Average Low
187.12 %
 57.67 %
-31.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 39
Sector # 331
S&P 500 # 2271
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Adma Biologics Inc 's cumulative twelve months Revenue were $ 511 millions, company would post below average annual Revenue growth of -31.86% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Adma Biologics Inc 's Revenue growth from the 113.75% growth in Mar 31 2026.

In the Healthcare sector 98 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 148 to 385.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 39
Healthcare Sector # 99
Overall # 385

Revenue TTM Y/Y Growth Statistics
High Average Low
187.12 %
57.67 %
-31.86 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 39
Sector # 331
S&P 500 # 2271




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ADMA's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Mettler toledo International Inc 4.48%$ 4.485 millions
Phibro Animal Health Corporation4.40%$ 4.405 millions
Align Technology inc 4.35%$ 4.355 millions
Opko Health Inc 4.32%$ 4.319 millions
Dariohealth Corp 4.29%$ 4.291 millions
Orthofix Medical Inc 4.15%$ 4.147 millions
Pediatrix Medical Group Inc 4.04%$ 4.040 millions
Nrc Health3.98%$ 3.978 millions
Bioventus Inc 3.76%$ 3.757 millions
Heron Therapeutics Inc 3.64%$ 3.640 millions
Prime Medicine Inc 3.50%$ 3.498 millions
Inogen Inc 3.04%$ 3.042 millions
Pacific Health Care Organization Inc2.79%$ 2.786 millions
Quidelortho Corp2.77%$ 2.769 millions
C4 Therapeutics Inc 2.75%$ 2.754 millions
Surgery Partners Inc 2.75%$ 2.748 millions
Lantheus Holdings Inc 2.69%$ 2.690 millions
Healthcare Services Group Inc 2.69%$ 2.686 millions
Adma Biologics Inc 2.61%$ 2.613 millions
Pfizer Inc2.60%$ 2.600 millions
Infusystem Holdings Inc2.59%$ 2.586 millions
Outset Medical Inc 2.49%$ 2.488 millions
3m Company2.46%$ 2.459 millions
Strata Critical Medical Inc 2.41%$ 2.408 millions
Nature s Sunshine Products inc 2.35%$ 2.350 millions
Solventum Corporation2.22%$ 2.221 millions
Adc Therapeutics Sa2.17%$ 2.171 millions
Moderna Inc 2.11%$ 2.113 millions
Co diagnostics Inc 1.98%$ 1.977 millions
Rxsight Inc 1.66%$ 1.660 millions


About Adma Biologics Inc Revenue Growth Rates (ADMA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Adma Biologics Inc (CIK 1368514).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001140361-26-031445
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Adma Biologics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.